The ProLung Test™
A new approach for early predictive detection of lung cancer.* 

*The ProLung Test is only available for purchase in the European Economic Area and European Free Trade Association Countries. It is for investigational use only in the United States.

Latest News


ProLung, Inc. Announces Closing of Private Placement Transaction with Proceeds of $8.2 million

Salt Lake City, UT, May 11, 2017 — ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the successful closing of its private placement. The private offering was expected to raise $5.2 million and was oversubscribed by $3.0 million to a total of $8.2 million.


Upcoming ProLung Appearances

ProLung, Inc. will be in attendance at the following upcoming events. Please visit the events page for more details.


Marcum Microcap Conference

June 15-16, 2017 | New York, NY


June 19-22, 2017 | San Diego, CA